XORTX Therapeutics
Tracked across 4 events · 24 articles · First seen Jun 12, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: XORTX Therapeutics Inc. is voluntarily delisting its common shares from the TSX Venture Exchange to reduce costs and administrative burden, aiming to optimize financing and focus on its XRx-026 program for gout treatment. This move is expected to improve its operational efficiency and long-term shareholder value.
Jun 12, 2026 · 6 articles
Business
Impact: XORTX loses its board chairman, a minor governance change. The company continues its clinical programs without disruption.
Jul 31, 2026 · 6 articles
Business
Impact: XORTX terminated its IR agreement, postponed its investor relations program, and is proceeding with voluntary delisting from the TSXV. These actions aim to reduce costs and regulatory complexity but may reduce investor visibility.
Aug 28, 2026 · 6 articles
Business
XORTX Therapeutics Inc., a pharmaceutical company, announced that following the completion of its voluntary delisting from the TSX Venture Exchange, it has re-engaged IR Agency LLC to provide investor relations and marketing services under a…
Impact: XORTX is the subject of the announcement, re-engaging IR Agency LLC after its TSX delisting. The move is part of its ongoing investor relations strategy.
Sep 08, 2026 · 6 articles
30
XORTX Therapeutics terminated agreement IR Agency LLCXORTX re-engages IR Agency...
ERGEN INTELLIGENCE
Track XORTX Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard